값Q4, 24TTM판매비·일반관리비——연구개발——영업 이익-1.05 M-4.31 M비영업 수익, 합계——이자비용(자본화한 이자 차감 후)——이자비용을 제외한 비영업 수익——비정상 수입/지출——세전소득42.84 M17.48 B지분법 손익——세금21.87 M-4.31 B비지배 지분——세후 기타 수익/비용——중단된 사업 부문 제외 순이익20.97 M21.79 B중단된 사업——순이익20.97 M21.79 B희석보정——우선배당——보통주주에게 귀속되는 희석 순이익20.97 M21.79 B주당 순이익(기본 EPS)——희석 주당 순이익 (희석 EPS)0.29191.05평균 발행주식수71.86 M—희석주식수71.86 M—EBITDA——EBIT——매출원가——기타 매출원가——감가상각 및 무형자산 상각 (현금흐름)1.05 M4.31 M
Sinovac Biotech Ltd - (Antigua/Barbudo)
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China. Its COVID-19 vaccine was the target of a covert disinformation campaign by the US government and a promotional social media astroturfing campaign by the Chinese government.